# RUBY (NCT03981796)

> A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03981796
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Tesaro, Inc.
- Conditions: Neoplasms
- Interventions: Dostarlimab; Placebo matching dostarlimab; Carboplatin; Paclitaxel; Niraparib; Placebo matching Niraparib
- Enrollment: 785
- Primary outcome: Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessment
- Primary outcome: Part 1: Overall survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 130
- Podcasts: 98
- X threads: 56

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ruby-nct03981796

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03981796", "email": "<work email>"}; the inbox owner confirms by the emailed link.